research use only
Cat.No.S5274
| Related Targets | CFTR CRM1 CD markers AChR Calcium Channel Potassium Channel GABA Receptor TRP Channel ATPase GluR |
|---|---|
| Other Sodium Channel Inhibitors | Camostat Mesilate A-803467 cariporide Tolperisone HCl Vinpocetine Veratramine Bulleyaconi cine A Ambroxol HCl Benzocaine Nefopam HCl |
| Molecular Weight | 347.22 | Formula | C14H7F6N3O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1262618-39-2 | -- | Storage of Stock Solutions |
|
|
| Synonyms | GS458967 | Smiles | C1=CC(=CC=C1C2=CN3C(=NN=C3C(F)(F)F)C=C2)OC(F)(F)F | ||
|
In vitro |
Ethanol : 46 mg/mL
DMSO
: 45 mg/mL
(129.6 mM)
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
late INa
0.13 μM
|
|---|---|
| In vitro |
GS967 (3 μM) has no significant effect on L- or T-type calcium channel currents or Na+-Ca2+ exchanger current (INCX), and 1 μM of this compound has minimal or no effect on the ATP-inhibited K+ current or on human cardiac ion channels expressed in human embryonic kidney 293 or Chinese hamster ovary cells. This compound is a novel Sodium Channel modulator specifically developed to inhibit persistent sodium current, with a 42-fold preference for persistent as opposed to peak current inhibition.
|
| In vivo |
GS967 protects against seizures and premature lethality in vivo. Chronic administration of this compound does not cause overt behavioural toxicity or sedation in wild-type mice at the effective anticonvulsant dose. It suppresses arrhythmogenicity evoked by ischaemia, hypokalaemia, and catecholamines in canine and porcine models
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.